Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma (EQUI-HIPPO)

Pilot Study Evaluating Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma and Describing the Evolution of Their Physical and Psychological Characteristics

On average, each year in the former region, 60 new patients under the age of 18 are treated for a brain tumor, with an active post-treatment follow-up file of 350 patients. Because of the significant sequelae induced by the disease or the treatments, these patients will very often require rehabilitative care.

The interest of involving the horse in the population of patients cured of a medulloblastoma but with important physical and psychological after-effects is to be able to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy based on the three-dimensional movement of the horse (hippotherapy).

Study Overview

• Status: Recruiting
• Conditions: Neuroblastoma
• Intervention / Treatment: Other: horse therapy

• Study Type: Interventional
• Enrollment (Estimated): 15
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Anne-Isabelle BERTOZZI, MD; Phone Number: 33 05 34 55 86 83; Email: bertozzi.ai@chu-toulouse.fr
• Study Contact Backup: Name: Françoise AURIOL, MD; Email: auriol.f@chu-toulouse.fr

Study Locations

• France
  • Toulouse, France, 31059
    • Recruiting
    • CHU de Toulouse
    • Contact: Anne-Isabelle BERTOZZI, MD; Phone Number: 0561772233; Email: bertozzi.ai@chu-toulouse.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 26 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• complete remission of medulloblastoma and after 5 years of the end of treatment
• living within 30 km away the riding center and/or less than 1 hour of transport
• informed consent

Exclusion Criteria:

• Landsky score below 50% for minors until 16 years old and Karnofsky score below 50% for patients over 16 years
• major under juridical protection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: horse therapy	Other: horse therapy; equitherapy and hippotherapy once a week during 16 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
number of sessions performed	number of sessions equitherapy and hippotherapy performed	16 weeks

Collaborators and Investigators

• Sponsor: University Hospital, Toulouse
• Investigators: Principal Investigator: Anne-Isabelle BERTOZZI, MD, University Hospital, Toulouse

Study record dates

Study Major Dates

• Study Start (Actual): April 3, 2023
• Primary Completion (Estimated): March 1, 2025
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: February 22, 2023
• First Submitted That Met QC Criteria: February 22, 2023
• First Posted (Actual): March 6, 2023

Study Record Updates

• Last Update Posted (Actual): July 13, 2023
• Last Update Submitted That Met QC Criteria: July 11, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: hippotherapy; equitherapy
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Medulloblastoma; Neuroblastoma
• Other Study ID Numbers: RC31/22/0218

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No